A NEW IDEA ON BIOTECH COMPANY ACORDA ON PATENT INVALIDATION $ACOR $MYL $TEVA

A NEW IDEA ON BIOTECH COMPANY ACORDA ON PATENT INVALIDATION $ACOR $MYL $TEVA

These posts were published on ZYX Short Sell Change Alert.

The short zone for Acorda Therapeutics (ACOR) is $24.50 to $26.40.  Since the stock is moving fast we want to get this to you quickly.  We will do another post shortly with more details. Maximum position size is 30% of full core position size.

MORE ON ACOR

We have a long history with Acorda Therapeutics (ACOR) from years ago when ACOR started talking about its drug Ampyra, long before the approval of the drug.  We have repeatedly been proven right and in the process have made a lot of money.

Ampyra is responsible for a significant part of the company’s revenues.  The news is that the Court of Appeals has ruled against ACOR patents on Ampyra.  This means that companies like Mylan (MYL) and Teva Pharmaceuticals (TEVA) will be able to make generic versions of Ampyra.

The target zone for the stock is $9 to $14.61 and possibly lower.

The issue is that this market is controlled by the momo crowd and this stock has been a favorite of Wall Street.  Every time something goes wrong with this company, Wall Street comes to its defense.  The reason may be that Wall Street makes money by selling stock in this company.  For this reason, fundamentals may not matter and the stock may run up again.  The stop zone is $28.15 to $29.35.  If Wall Street does not come to the defense of this company and the stock moves higher just from the momo crowd buying, the tentative plan is to add to this position.

 

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

TAKE MORE PROFITS ON ACORDA AND EXIT THE POSITION WITH A PLAN TO RE-ENTER $ACOR

This post was just published on ZYX Short Sell Change Alert. On a fundamental basis, the prior target makes sense.  However since Acorda ...

TAKE PARTIAL PROFITS ON ACORDA $ACOR

These posts were published on ZYX Short Sell Change Alert. Consider taking profits on one-half of Acorda (ACOR) in the zone of $20 ...

BE FOREWARNED IF YOU ARE CHASING DIVIDENDS $TEVA $MYL $PRGO $RDY $ABX $MCK $CAH $ESRX

  Dividend-chasing is in vogue. Given low interest rates, many investors say they have no other choice. Such thinking leads to costly ...

GREAT PROFITS ON OUR SHORT ON MS WALKING DRUG COMPANY ACORDA, STOCK CRUSHED ON PATENT RULING $ACOR

This post was just published on ZYX Short Sell Change Alert. ACOR is short from $48.73.  The stock was halted at $20.33, down $6.44.  ...

TRUMP’S ‘OBAMACARE LITE’ PRESENTS OPPORTUNITIES AND PERILS FOR INVESTORS $XBI $MDT $BSX $EW $CYH $THC $PFE $JNJ $MRK $BMY $TEVA $MYL

Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside ...

TAKE PARTIAL PROFITS ON MYLAN $MYL

This post was just published on ZYX Buy Change Alert. MYL is long from an average price of $37.78.  As of this writing ...

A NEW IDEA ON MOMENTA, AFTER RECENT GAIN OF 74% THE DIP IS AN OPPORTUNITY TO ENTER AGAIN $MNTA $TEVA $PFE

This post was just published on ZYX Buy Change Alert. On February 1st we issued a call to take profits on MNTA.  Depending ...

MOMENTA PHARMACEUTICALS JUMPS ON COPAXONE RULING, TAKE PROFITS AND EXIT THE POSITION IF STILL HOLDING $MNTA $MYL $TEVA

This post was published on ZYX Buy Change Alert. MNTA has an average price of $11.31.  As of this writing it is trading ...

MYLAN BENEFITING FROM COPAXONE $MYL $TEVA

This post was just published on ZYX Buy Change Alert. MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug.  ...

REDUCE MYLAN ON TRUMP COMMENT $MYL

This post was published on ZYX Buy Change Alert.  Consider reducing MYL position to 30% of the full core position size if holding ...

HOW THE ‘JANUARY EFFECT’ IN STOCKS CAN HELP YOU POCKET QUICK GAINS $CYH $FIT $KANG $MYL $VRX $THC $HCA

  The so-called January Effect offers an opportunity to potentially make about 30% in three months in the stock market. The ...

PLAN ON MYLAN: TEVA PHARMACEUTICAL, TAX LOSS SELLING AND TRUMP $MYL $TEVA

This post was just published on ZYX Buy Change Alert. TEVA MYL is a generic drug manufacturer.  The earlier decline in the stock was ...

SMART MONEY LIGHTLY STEPS INTO MYLAN $MYL $ENDP $IPXL $LCI $TARO $TEVA

This post was just published on ZYX Buy Change Alert. Algorithms at The Arora Report have been detecting smart money lightly stepping into ...

UPDATE ON MYLAN $MYL $TEVA $LCI $IPXL $ENDP $TARO

This post was just published on ZYX Buy Change Alert. All generic drug manufacturers are falling on the news that U. S. prosecutors ...

MYLAN UP ABOUT 10% ON DOJ SETTLEMENT $MYL

This post was just published on ZYX Buy Change Alert. MYL has reached a $465 million settlement with the Department of Justice on ...

INITIATE OR ADD TO MYLAN $MYL

This post was just published on ZYX Buy Change Alert. MYL is long from an average price of $38.47.  As of this writing ...

UPDATE ON MYLAN LABS $MYL

This post was just published on ZYX Buy Change Alert. MYL is falling again on news of a Senator posting on her ...

A NEW IDEA ON MYLAN LABS $MYL

This post was just published on ZYX Buy Change Alert. MYL is primarily a drug manufacturer but also has a few branded ...

GET AHEAD OF SUPREME COURT ON OBAMACARE, TAKE PROFITS AND REVIEW HEALTHCARE POSITIONS $CYH $THC $RAD $WBA $MOH $CNC $PRGO $MYL #OBAMACARE

This post was just published on ZYX Buy Change Alert. The Supreme Court is likely to make a ruling on Obamacare this ...

SMART MONEY SELLS INTO MYLAN RISE FOR A GOOD REASON $MYL $FRX $ACT $TEVA

Since the Feb. 18 announcement that Actavis would acquire Forest Laboratories for about $25 billion, which caused Forest Laboratories stock to leap ...

Follow

Get every new post delivered to your Inbox

Join other followers